Form 4: Agios Pharmaceuticals CCO Exercises Performance Share Units, Sells Shares for Tax Obligations

Agios Pharmaceuticals' Chief Commercial Officer, Tsveta Milanova, acquired 6,000 common shares through the vesting of performance share units and subsequently sold 2,770 shares to cover tax withholding obligations, as disclosed in a recent SEC Form 4 filing.

Summary

• Tsveta Milanova, Chief Commercial Officer of Agios Pharmaceuticals, Inc. (AGIO), acquired 6,000 shares of common stock on June 24, 2025, through the vesting of performance share units (PSUs).
• These PSUs were granted on March 1, 2023, and vested as 50% of the underlying shares upon the achievement of a specified research milestone.
• The research milestone was determined to have been met on June 24, 2025, triggering the vesting.
• Concurrently, Ms. Milanova sold 2,770 shares of common stock at a price of $33.54 per share to cover tax withholding obligations related to the vesting.
• This sale was executed pursuant to a Rule 10b5-1(c) pre-arranged trading plan established on March 1, 2023.
• Following these transactions, Ms. Milanova directly beneficially owns 26,122 shares of common stock and 6,000 performance share units (representing the unvested portion tied to a regulatory milestone).

Sentiment

Score: 7

Explanation: The document indicates the achievement of a research milestone, which is positive for the company's pipeline. The associated share transactions (vesting and tax-related sale) are routine and expected events for executive compensation, executed under a pre-planned arrangement, which adds transparency.

Positives

• Achievement of a specified research milestone on June 24, 2025, leading to the vesting of 50% of the performance share units, indicating progress in the company's research and development efforts.
• The transaction was conducted under a Rule 10b5-1(c) plan, indicating a pre-planned and transparent sale for tax purposes rather than a discretionary sale based on new information.

Negatives

• The sale of 2,770 shares, even if for tax purposes, represents a reduction in the direct beneficial ownership of common stock by a key executive.

Future Outlook

The document indicates that the remaining 50% of the performance share units will vest upon the achievement of a specified regulatory milestone, suggesting future progress in the company's pipeline.

Management Comments

• Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units.
• This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2023.
• The performance criteria for the specified research milestone was determined to have been met on June 24, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares.
• Vested shares will be delivered to the reporting person within three business days after such shares become vested.

Industry Context

This Form 4 filing reflects standard executive compensation practices in the biotechnology and pharmaceutical industry, where performance-based equity awards like PSUs are common. The vesting tied to a research milestone is typical for a company like Agios Pharmaceuticals, which is focused on drug development, indicating progress in its R&D pipeline. The sale of shares to cover tax obligations upon vesting is also a routine event for executives.

Comparison to Industry Standards

• The use of performance share units (PSUs) tied to specific research and regulatory milestones aligns with best practices in the biopharmaceutical industry for executive compensation, incentivizing the achievement of strategic corporate objectives.
• The execution of the share sale under a Rule 10b5-1 plan is a standard corporate governance practice that enhances transparency and mitigates concerns about insider trading, consistent with practices at comparable publicly traded pharmaceutical companies.
• The vesting of 50% of PSUs upon a research milestone is a positive indicator of R&D progress, a key value driver in the biotech sector, comparable to similar milestone achievements reported by peers like Vertex Pharmaceuticals or Sarepta Therapeutics in their respective development pipelines.

Corporate Governance

Related Party Transactions

• The transaction involves an executive (Tsveta Milanova) and the company (Agios Pharmaceuticals, Inc.) regarding equity compensation, which is a common type of related party transaction in the context of executive compensation.

Stakeholder Impact

• Shareholders: The vesting of PSUs and subsequent sale for tax purposes are routine events that provide transparency into executive compensation and share ownership. The achievement of a research milestone could be viewed positively as it indicates progress in the company's R&D.
• Employees: The vesting of performance-based equity awards can serve as a positive signal regarding the company's progress and its commitment to incentivizing key personnel.

Next Steps

• The remaining 50% of the performance share units are expected to vest upon the achievement of a specified regulatory milestone.
• Vested shares will be delivered to the reporting person within three business days after they become vested.

Key Dates

Recommendation

Keywords

Agios Pharmaceuticals, AGIO, SEC Form 4, insider trading, beneficial ownership, stock vesting, performance share units, Rule 10b5-1, executive compensation, Tsveta Milanova, Chief Commercial Officer, research milestone